RU2015146419A - Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl - Google Patents

Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl Download PDF

Info

Publication number
RU2015146419A
RU2015146419A RU2015146419A RU2015146419A RU2015146419A RU 2015146419 A RU2015146419 A RU 2015146419A RU 2015146419 A RU2015146419 A RU 2015146419A RU 2015146419 A RU2015146419 A RU 2015146419A RU 2015146419 A RU2015146419 A RU 2015146419A
Authority
RU
Russia
Prior art keywords
seq
icosl
specific antigen
binding molecule
antigen binding
Prior art date
Application number
RU2015146419A
Other languages
English (en)
Russian (ru)
Inventor
Каролин Джейн БАРЕЛЛЕ
Уильям Джеймс Джонатан ФИНЛЕЙ
Альфредо ДАРМАНИН-ШИАН
Original Assignee
Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин filed Critical Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин
Publication of RU2015146419A publication Critical patent/RU2015146419A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
RU2015146419A 2013-04-23 2014-04-23 Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl RU2015146419A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058276 WO2014173975A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Publications (1)

Publication Number Publication Date
RU2015146419A true RU2015146419A (ru) 2017-05-26

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015146419A RU2015146419A (ru) 2013-04-23 2014-04-23 Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
RU2015146418A RU2015146418A (ru) 2013-04-23 2014-04-23 Библиотека синтетических специфически связывающих молекул

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015146418A RU2015146418A (ru) 2013-04-23 2014-04-23 Библиотека синтетических специфически связывающих молекул

Country Status (11)

Country Link
US (3) US10202438B2 (enExample)
EP (3) EP2989204B1 (enExample)
JP (2) JP6616284B2 (enExample)
KR (2) KR102320189B1 (enExample)
CN (2) CN105492610B (enExample)
AU (3) AU2014257565A1 (enExample)
BR (2) BR112015026729A2 (enExample)
CA (2) CA2909921C (enExample)
DK (1) DK2989203T3 (enExample)
RU (2) RU2015146419A (enExample)
WO (2) WO2014173959A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー
CA2953569A1 (en) 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
CN107074961A (zh) * 2014-11-03 2017-08-18 默克专利股份公司 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
ITUB20151014A1 (it) 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3688030B1 (en) 2017-09-27 2024-12-11 Elasmogen Ltd Specific binding molecules
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US20220130494A1 (en) * 2019-02-11 2022-04-28 Neal W. Woodbury Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
WO2021222546A1 (en) * 2020-05-01 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for identifying nanobodies and nanobody affinities
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
AU2002319544B2 (en) * 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
DE602004032042D1 (de) 2003-08-27 2011-05-12 Proterec Ltd Bibliotheken rekombinanter chimärischer proteine
WO2005118629A1 (en) * 2004-06-02 2005-12-15 Diatech Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
JPWO2006003999A1 (ja) 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 ヒト抗ヒトｂ７ｒｐ−１抗体およびその抗体フラグメント
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US8293233B2 (en) * 2005-03-25 2012-10-23 National Research Council Of Canada Method for isolation of soluble polypeptides
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
SG196835A1 (en) 2005-07-18 2014-02-13 Amgen Inc Human anti-b7rp1 neutralizing antibodies
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
AU2009301631A1 (en) 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
US20110231359A1 (en) * 2008-10-07 2011-09-22 Zap Holdings Limited Synchronization of relational databases with olap cubes
US8496933B2 (en) * 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
US20140154241A1 (en) * 2010-12-03 2014-06-05 Cyclogenix Ltd Binding peptides i
WO2013167883A1 (en) * 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
JP6616284B2 (ja) 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Also Published As

Publication number Publication date
EP2989204A1 (en) 2016-03-02
BR112015026716A2 (pt) 2017-09-05
DK2989203T3 (da) 2020-02-17
CA2909921A1 (en) 2014-10-30
BR112015026729A2 (pt) 2017-09-05
KR20160015220A (ko) 2016-02-12
JP6616284B2 (ja) 2019-12-04
CN105492610A (zh) 2016-04-13
RU2015146418A (ru) 2017-05-26
CN105492610B (zh) 2020-08-25
AU2014257549A1 (en) 2015-11-26
WO2014173959A3 (en) 2015-01-29
CN105531370A (zh) 2016-04-27
US20200002403A1 (en) 2020-01-02
AU2014257565A1 (en) 2015-11-26
EP2989203A2 (en) 2016-03-02
EP3683312A3 (en) 2020-09-16
US20160068600A1 (en) 2016-03-10
KR102320189B1 (ko) 2021-11-03
EP3683312A2 (en) 2020-07-22
KR20160010466A (ko) 2016-01-27
US11459377B2 (en) 2022-10-04
EP2989204B1 (en) 2019-03-20
CA2909923A1 (en) 2014-10-30
JP6591964B2 (ja) 2019-10-16
RU2015146418A3 (enExample) 2018-05-07
CA2909921C (en) 2022-12-06
WO2014173975A1 (en) 2014-10-30
JP2016524592A (ja) 2016-08-18
AU2014257549B2 (en) 2019-04-18
JP2016524463A (ja) 2016-08-18
EP3683312B1 (en) 2022-09-07
AU2019206064A1 (en) 2019-08-08
US10202438B2 (en) 2019-02-12
EP2989203B1 (en) 2019-11-13
US20160176951A1 (en) 2016-06-23
US10472410B2 (en) 2019-11-12
WO2014173959A2 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
RU2015146419A (ru) Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
JP2016524592A5 (enExample)
JP6435381B2 (ja) マトリクスメタロプロティナーゼ９に対する抗体
JP7829773B2 (ja) Ｉｌ２７受容体結合に関連する組成物および方法
CN110891972B (zh) 对ror1和cd3的双特异性抗体
ES2779977T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
JP2016524463A5 (enExample)
RU2017107773A (ru) Антитела, специфичные к ммр9
EA202190669A1 (ru) Процесс получения вакцинной композиции
HRP20200036T1 (hr) Postupci liječenja tauopatije
HRP20220918T1 (hr) Anti-transtiretinska antitijela
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
Melo et al. Golimumab (anti-TNF monoclonal antibody): where we stand today
RU2016135962A (ru) Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI
RU2009120536A (ru) Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf)
JP2014500862A5 (enExample)
HK1259326A1 (zh) 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
HK1259324A1 (zh) 淀粉样蛋白β表位及其抗体
Silva-Pilipich et al. A small virus to deliver small antibodies: new targeted therapies based on AAV delivery of nanobodies
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
AU2014331584A1 (en) Dual specific binding proteins directed against immune cell receptors and TLR signaling autoantigens
RU2018121413A (ru) Антитело ANTI-PCSK9 и его применение
RU2018117651A (ru) Бактерицидное моноклональное антитело, нацеленное на klebsiella pneumoniae
JP2017526618A5 (enExample)
Menzies et al. Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180619